-
Prognostication in chronic lymphocytic leukemia Semin. Hematol. (IF 3.6) Pub Date : 2024-03-01 Riccardo Moia, Gianluca Gaidano
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. CLL is a highly heterogeneous disease: some patients may never require therapy and other relapse several times after different therapeutic strategies. Therefore, in CLL, prognostic markers are essential to capture high-risk patients for different clinical endpoints including early treatment requirement, early
-
Metabolic reprogramming in the CLL TME; potential for new therapeutic targets Semin. Hematol. (IF 3.6) Pub Date : 2024-02-15 Helga Simon-Molas, Chiara Montironi, Anna Kabanova, Eric Eldering
-
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia Semin. Hematol. (IF 3.6) Pub Date : 2024-02-07 Inhye E. Ahn, Matthew S. Davids
Therapeutic targeting of apoptosis with small molecule B-cell lymphoma 2 (BCL-2) inhibition with venetoclax is highly efficacious in CLL, leading to sustained deep responses, particularly among patients with treatment-naïve disease with favorable prognostic markers. Patients with unfavorable genetic characteristics such as aberration and unmutated IGHV may also derive durable benefits, but their remission
-
Clonal hematopoiesis Semin. Hematol. (IF 3.6) Pub Date : 2024-02-02 J, a, r, o, s, l, a, w, , P, ., , M, a, c, i, e, j, e, w, s, k, i
Abstract not available
-
Clonal hematopoiesis and autoimmunity Semin. Hematol. (IF 3.6) Pub Date : 2024-02-02 Ashwin Kishtagari, Robert W. Corty, Valeria Visconte
Clonal hematopoiesis (CH) has been associated with aging, occurring in about 10% of individuals aged > 70 years, and immune dysfunction. Aged hematopoietic stem and progenitor cells exhibit pathological changes in immune function and activation of inflammatory pathways. CH clones commonly harbor a loss of function mutation in or , which causes increased expression of inflammatory signaling genes, a
-
TET2 mutation as prototypic clonal hematopoiesis lesion Semin. Hematol. (IF 3.6) Pub Date : 2024-02-02 Luca Guarnera, Babal K. Jha
Loss of function mutation () is one of the most frequently observed lesions in clonal hematopoiesis (CH). TET2 a member TET-dioxygenase family of enzymes that along with TET1 and TET3, progressively oxidize 5-methyl cytosine (mC) resulting in regulated demethylation of promoter, enhancer and silencer elements of the genome. This process is critical for efficient transcription that determine cell lineage
-
Clonal hematopoiesis in the setting of hematopoietic cell transplantation Semin. Hematol. (IF 3.6) Pub Date : 2024-02-01 Christopher J. Gibson, R. Coleman Lindsley, Lukasz P. Gondek
Clonal hematopoiesis (CH) in autologous transplant recipients and allogeneic transplant donors has genetic features and clinical associations that are distinct from each other and from non-cancer populations. CH in the setting of autologous transplant is enriched for mutations in DNA damage response pathway genes and is associated with adverse outcomes, including an increased risk of therapy-related
-
Introduction to series: Diffuse large B-cell lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2024-01-26 Sonali M. Smith, Laura Pasqualucci
Abstract not available
-
The molecular map of CLL and Richter's syndrome Semin. Hematol. (IF 3.6) Pub Date : 2024-01-23 Amit Sud, Erin M. Parry, Catherine J. Wu
Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's syndrome (RS) provides a comprehensive model of cancer evolution, notable for the marked morphological transformation and distinct clinical phenotypes. High-throughput sequencing of large cohorts of patients and single-cell studies
-
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities Semin. Hematol. (IF 3.6) Pub Date : 2024-01-22 Elizabeth A. Brem, Laurie H. Sehn
Diffuse large B-cell lymphoma (DLBCL) is an aggressive but often curable malignancy. Older patients, especially those 80 years and older, have poor outcomes compared to those < 60, likely due to a number of reasons including disease biology, comorbidities, and treatment intolerance. Prospective data informing the treatment of older patients and those with multiple co-morbidities is limited. Here, we
-
A Tower of Babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS Semin. Hematol. (IF 3.6) Pub Date : 2024-01-19 Carlos Bravo-Perez, Carmelo Gurnari
With the advent of outperforming and massive laboratory tools, such as multiparameter flow cytometry and next-generation sequencing, hematopoietic cell clones with putative abnormalities for a variety of blood malignancies have been appreciated in otherwise healthy individuals. These conditions do not fulfill the criteria of their presumed cancer counterparts, and thus have been recognized as their
-
The Crossroads of Cancer Therapies and Clonal Hematopoiesis Semin. Hematol. (IF 3.6) Pub Date : 2024-01-18 Abhay Singh, Suresh Balasubramanian
The intricate interplay between Clonal Hematopoiesis (CH) and the repercussions of cancer therapies has garnered significant research focus in recent years. Previously perceived as an age-related phenomenon, CH is now closely linked to inflammation ("Inflammaging") and cancer, impacting leukemogenesis, cancer progression, and treatment responses. This review explores the complex interplay between CH
-
Immune-driven clonal cell selection at the intersection among cancer, infectious diseases, autoimmune disorders, and senescence Semin. Hematol. (IF 3.6) Pub Date : 2024-01-17 Simona Pagliuca, Francesca Ferraro
Immune surveillance mechanisms play a crucial role in maintaining lifelong immune homeostasis in response to pathologic stimuli and aberrant cell states. However, their persistence, especially in the context of chronic antigenic exposure, can create a fertile ground for immune evasion. These escaping cell phenotypes, harboring a variety of genomic and transcriptomic aberrances, chiefly in human leukocyte
-
Germline Predisposition for Clonal Hematopoiesis Semin. Hematol. (IF 3.6) Pub Date : 2024-01-14 Yasuo Kubota, Aaron D. Viny
Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term
-
CLONAL HEMATOPOIESIS IN CHILDREN WITH PREDISPOSING CONDITIONS Semin. Hematol. (IF 3.6) Pub Date : 2024-01-14 Enrico Attardi, Seth J Corey, Marcin W Wlodarski
Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential
-
Vaccinations in Patient with Chronic Lymphocytic Leukemia Semin. Hematol. (IF 3.6) Pub Date : 2024-01-06 Elizabeth R. Francis, Jennifer Vu, Catherine Ostos Perez, Clare Sun
Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunction resulting in heightened susceptibility to infections and elevated rates of morbidity and mortality. A key strategy to mitigate infection-related complications has been immunization against common pathogens. However, the immunocompromised status of CLL patients poses challenges in eliciting an adequate humoral and cellular immune
-
Transforming CLL Management with Immunotherapy: Investigating the Potential of CAR T-Cells and Bispecific Antibodies Semin. Hematol. (IF 3.6) Pub Date : 2024-01-05 Azra Borogovac, Tanya Siddiqi
Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies or T-cell engagers, have revolutionized the treatment landscape for various B-cell malignancies, including B-acute lymphoblastic leukemia and many non-Hodgkin lymphomas. Despite their significant impact on these malignancies, their application in chronic lymphocytic leukemia (CLL) management is still largely
-
B cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: key to understanding disease biology and stratifying patients Semin. Hematol. (IF 3.6) Pub Date : 2023-12-26 Andreas Agathangelidis, Thomas Chatzikonstantinou, Kostas Stamatopoulos
Sequence convergence, otherwise stereotypy, of B cell receptor immunoglobulin (BcR IG) from unrelated patients is a distinctive feature of the IG gene repertoire in chronic lymphocytic leukemia (CLL) whereby patients expressing a particular BcR IG archetype are classified in groups termed stereotyped subsets. From a biological perspective, the fact that a considerable fraction (∼41%) of patients with
-
Role of the tumor microenvironment in CLL pathogenesis Semin. Hematol. (IF 3.6) Pub Date : 2023-12-26 Alexander F. vom Stein, Michael Hallek, Phuong-Hien Nguyen
Chronic lymphocytic leukemia (CLL) cells extensively interact with and depend on their surrounding tumor microenvironment (TME). The TME encompasses a heterogeneous array of cell types, soluble signals and extracellular vesicles, which contribute significantly to CLL pathogenesis. CLL cells and the TME cooperatively generate a chronic inflammatory milieu, which reciprocally reprograms the TME and activates
-
Integration of PET in DLBCL Semin. Hematol. (IF 3.6) Pub Date : 2023-12-24 Katharine L Lewis, Judith Trotman
F-fluorodeoxyglucose positron emission tomography-computerized tomography (FDG-PET/CT) is the gold-standard imaging modality for staging and response assessment for most lymphomas. This review focuses on the utility of FDG-PET/CT, and its role in staging, prognostication and response assessment in diffuse large B-cell lymphoma (DLBCL), including emerging possibilities for future use.
-
Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options Semin. Hematol. (IF 3.6) Pub Date : 2023-12-14 N. Fabbri, A. Mussetti, A. Sureda
In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy. However, 30%-40% relapse after initial response to first-line therapy and, out of them, 20%-50% are refractory or experience early relapse. The second-line therapy algorithm for DLBCL has recently evolved, thanks to the recent
-
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023 Semin. Hematol. (IF 3.6) Pub Date : 2023-12-12 Christine E. Ryan, Caron A. Jacobson
Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has profoundly changed the management of relapsed/refractory large-B-cell lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell products for LBCL: axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Two of these (axi-cel & liso-cel) are approved
-
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? Semin. Hematol. (IF 3.6) Pub Date : 2023-12-05 Hannah Kinoshita, Catherine M. Bollard, Keri Toner
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed or refractory diffuse large B cell lymphoma (DLBCL) with 3 CD19 targeting products now FDA-approved for this indication. However, up to 60% of patients ultimately progress or relapse following CAR-T cell therapy. Mechanisms of resistance to CAR-T cell therapy in patients with DLBCL are likely multifactorial and
-
Biological, prognostic and therapeutic impact of the epigenome in CLL Semin. Hematol. (IF 3.6) Pub Date : 2023-12-01 Alba Maiques-Diaz, Jose Ignacio Martin-Subero
Chronic lymphocytic leukemia (CLL) is characterized by widespread alterations in the genetic and epigenetic landscapes which seem to underlie the variable clinical manifestations observed in patients. Over the last decade, epigenomic studies have described the whole-genome maps of DNA methylation and chromatin features of CLL and normal B cells, identifying distinct epigenetic mechanisms operating
-
Biological heterogeneity in diffuse large B-cell lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-12-01 Laura K. Hilton, David W. Scott, Ryan D. Morin
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous both in clinical outcomes and the underlying disease biology. Over the last 2 decades, several different approaches for dissecting biological heterogeneity have emerged. Gene expression profiling (GEP) stratifies DLBCL into 3 broad groups (ABC, GCB, and DZsig/MHG), each with parallels to different normal mature B cell developmental states and prognostic
-
Evidence-based management of primary and secondary CNS lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-12-01 Jahanzaib Khwaja, Lakshmi Nayak, Kate Cwynarski
Central nervous system (CNS) lymphoma has traditionally had very poor outcomes however advances in management have resulted in dramatic improvements and long-term survival of patients. We describe the evidence for treatment strategies for these aggressive disorders. In primary CNS lymphoma there are randomized trial data to inform treatment decisions but these are lacking to guide management in secondary
-
Epidemiology and etiology of diffuse large B-cell lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-11-27 Sophia S. Wang
As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher
-
Antibody and immunotherapy in diffuse large B-cell lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-11-23 Allison Barraclough, Eliza A. Hawkes
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and a heterogeneous B-cell disease. The majority of patients with newly diagnosed disease are cured with first-line combination immunochemotherapy treatment however, those who experience treatment failure have dismal outcomes. Antibody therapies and immunotherapy have provided the single most major advance in the treatment of DLBCL in
-
DLBCL arising from indolent lymphomas: How are they different? Semin. Hematol. (IF 3.6) Pub Date : 2023-11-23 Erin M. Parry, Sandrine Roulland, Jessica Okosun
Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 3.6) Pub Date : 2023-11-14
Abstract not available
-
-
Debate: Should the loss of disability adjusted life years (DALY) define the focus of Global Hematology?: The case for prioritizing capacity building in anemia management and blood transfusion Semin. Hematol. (IF 3.6) Pub Date : 2023-09-30 David J. Roberts, Aggrey Dhabangi
Setting priorities in healthcare is always contentious given the array of possible services at primary, secondary, and tertiary levels of care, not to mention potential public health interventions. The central goals in global policy have been reducing inequity within and between countries, protecting vulnerable groups (particularly women and children) and reducing the major communicable diseases which
-
Special edition of the Seminars in Hematology series on Global Hematology Care Semin. Hematol. (IF 3.6) Pub Date : 2023-09-27 Anna Schuh
Abstract not available
-
The future of aplastic anemia treatment in Brazil: Lessons learned for global hematology Semin. Hematol. (IF 3.6) Pub Date : 2023-09-24 Rodrigo T. Calado
Aplastic anemia (AA) is a rare serious hematologic disorder caused by hematopoietic stem cell failure in maintaining hematopoiesis. AA is virtually fatal if not treated, and diagnosis and therapy require extensive hematologic infrastructure. Academic medical centers in Brazil have continuously and significantly contributed to diagnostic tools and therapy development, from novel transplant strategies
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 3.6) Pub Date : 2023-09-13
Abstract not available
-
How to set up a clinical research center in Brazil, as an example of a middle-income country Semin. Hematol. (IF 3.6) Pub Date : 2023-09-04 Eduardo Flávio Oliveira Ribeiro, Ana Amélia Morais de Lacerda Mangueira Belmiro, Lenisa Cezar Vilas Boas, Carsten Utoft Niemann
In health care, innovation is a core part of the process that pushes advances forward. Drug and device development follow a step-by-step process from the discovery of a molecule to the final product. While patent filing and preclinical studies are usually performed by academic centers or start-ups, the clinical development is usually performed by pharmaceutical companies. To assess safety, efficacy
-
The case for prioritizing malignant hematology services in low- and middle-income countries Semin. Hematol. (IF 3.6) Pub Date : 2023-09-02 Satish Gopal
A clear case for can be made for prioritizing malignant hematology services in low- and middle-income countries based on large public health burden, convincing demonstrations of cure and control, innovation opportunities with likely worldwide implications, and sizable returns on investment for health systems and societies. We must now ensure that need and opportunity are matched by commensurate levels
-
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam Semin. Hematol. (IF 3.6) Pub Date : 2023-09-01 Bach Quoc Khanh, Vo Thi Thanh Binh, Nguyen Ha Thanh, Dao Phan Thu Huong, Do Thi Thuy, Nguyen Khanh Ha, Richard W. Childs
Through collaboration with international experts, our institution established a highly active and successful hematopoietic stem cell transplant program, providing access to this potentially curative treatment modality for patients with a variety of benign and malignant hematological diseases. The initial development of an autologous stem cell transplant program provided our institution with the infrastructure
-
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa Semin. Hematol. (IF 3.6) Pub Date : 2023-08-24 Mwashungi Ally, Emmanuel Balandya
Sickle cell disease (SCD) is the most common life-threatening monogenic disorder in the world. The disease is highly prevalent in malaria endemic areas with over 75% of patients residing in Sub-Saharan Africa (SSA). It is estimated that, without proper care, up to 90% of children with SCD will not celebrate their fifth birthday. Early identification and enrolment into comprehensive care has been shown
-
Special issue on circulating tumor DNA: Introductory editorial Semin. Hematol. (IF 3.6) Pub Date : 2023-08-19 Adalgisa Condoluci, Davide Rossi
Abstract not available
-
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services Semin. Hematol. (IF 3.6) Pub Date : 2023-08-01 Clara Chamba, William Mawalla
The world is moving towards precision medicine for cancer. This movement goes hand in hand with the development of newer advanced technologies for early, precise diagnosis of cancer and personalized treatment plans with fewer adverse effects for the patient. Liquid biopsy is one such advancement. At the same time, it has the advantage of minimal invasion and avoids serial invasive biopsies. In countries
-
Circulating tumor DNA in NK/T and peripheral T cell lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-07-26 Yu-Jia Huo, Wei-Li Zhao
Natural killer (NK)/T-cell lymphomas (NK/TCL) and peripheral T-cell lymphomas (PTCL) are aggressive hematological malignancies. With the development of next-generation sequencing, circulating tumor DNA (ctDNA) can be detected by several techniques with clinical implications. So far, the effect of ctDNA in pretreatment prognosis prediction, longitudinal monitoring of treatment response and surveillance
-
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence Semin. Hematol. (IF 3.6) Pub Date : 2023-07-22 Yupawadee Kantabanlang, Cheng-Pei Lin, Kittikorn Nilmanat, Ping Guo
Patients with hematologic malignancies often experience fatigue, lack of vitality, and energy, and high psychological distress. High levels of unmet care needs of patients with hematologic malignancies in Asia were identified. This review provides an overview of current evidence on the experiences and palliative care needs of patients with hematologic malignancies and their families and the barriers
-
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma? Semin. Hematol. (IF 3.6) Pub Date : 2023-07-15 María José Mela Osorio, Carolina Pavlovsky, Miguel Arturo Pavlovsky
Health equity is today an important objective to evenly reach the population among different health care systems. This article will focus on diagnosis and treatment access inequalities in Argentina. Although different aspects must be optimized to overcome access barriers worldwide, access inequalities in some regions of Argentina may depend basically on the type of health coverage or insurance. Health
-
Cell-free DNA in large B-cell lymphoma: MRD and beyond Semin. Hematol. (IF 3.6) Pub Date : 2023-07-07 Brian J. Sworder, David M. Kurtz
Large B-cell lymphomas (LBCLs) are a strikingly diverse set of diseases, including clinical, biological, and molecular heterogeneity. Despite a wealth of information resolving this heterogeneity in the research setting, applying molecular features routinely in the clinic remains challenging. The advent of circulating tumor DNA (ctDNA) liquid biopsies promises to unlock additional molecular information
-
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana Semin. Hematol. (IF 3.6) Pub Date : 2023-07-07 Christine Nyonator, Emefa Amoah, Etta Forson Addo, Maureen Mukanga, Augustine Kwabena Asubonteng, Kwaku Ohene-Frempong, Jonathan Michael Spector, Solomon Fiifi Ofori-Acquah
Novartis, a global medicines company, and the Sickle Cell Foundation of Ghana (SCFG), an advocacy organization, have endeavored to support the implementation of global best practices in the care of people living with sickle cell disease (SCD) in Africa, and to address unmet needs relating to this condition on the continent. Beginning in 2019, a multifaceted SCD program was implemented in Ghana through
-
Clinical applications of circulating tumor DNA in central nervous system lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-07-04 Anna Katharina Foerster, Eliza M. Lauer, Florian Scherer
Detection and characterization of circulating tumor DNA (ctDNA) in body fluids have the potential to revolutionize management of patients with lymphoma. Minimal access to malignant DNA through a simple blood draw or lumbar puncture is particularly appealing for CNS lymphomas (CNSL), which cannot be easily or repeatedly sampled without invasive surgeries. Profiling of ctDNA provides a real-time snapshot
-
Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas Semin. Hematol. (IF 3.6) Pub Date : 2023-06-30 Leo Meriranta, Esa Pitkänen, Sirpa Leppä
Liquid biopsies utilizing plasma circulating tumor DNA (ctDNA) are anticipated to revolutionize decision-making in cancer care. In the field of lymphomas, ctDNA-based blood tests represent the forefront of clinically applicable tools to harness decades of genomic research for disease profiling, quantification, and detection. More recently, the discovery of nonrandom fragmentation patterns in cell-free
-
Clinical applications of circulating tumor DNA in indolent B-cell lymphomas Semin. Hematol. (IF 3.6) Pub Date : 2023-06-29 Rahul Lakhotia, Mark Roschewski
Indolent B-cell lymphomas are generally incurable with standard therapy and most patients have a prolonged disease course that includes multiple treatments and periods of time in which they do not require therapy. Currently available tools to monitor disease burden and define response to treatment rely heavily on imaging scans that lack tumor specificity are unable to detect disease at the molecular
-
Clinical applications of circulating tumor DNA in Hodgkin lymphoma Semin. Hematol. (IF 3.6) Pub Date : 2023-06-28 Jan-Michel Heger, Justin Ferdinandus, Julia Mattlener, Sven Borchmann
Hodgkin lymphoma is a B-cell lymphoma often affecting young adults. Outcomes following intensive chemo- and radiotherapy are generally favourable but leave patients at high risk for early and late toxicities frequently reducing quality of life. Relapsed/refractory disease is regularly difficult to treat and ultimately results in death in a relevant subset of patients. Current strategies for risk stratification
-
Setting up a network of comprehensive care for patients with chronic myeloid leukemia: Lessons learned from Tanzania Semin. Hematol. (IF 3.6) Pub Date : 2023-06-25 Ahlam Nasser, Hamisa Iddy
Over the last 2 decades, the introduction of targeted therapies and the advances in the detection of BCR::ABL1 oncogene have dramatically improved comprehensive care for patients with Chronic myeloid leukemia (CML). The once deadly malignancy has now transformed into a chronic disease with an overall patient survival approaching that of the age-matched general population. While excellent prognoses
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 3.6) Pub Date : 2023-06-13
Abstract not available
-
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care Semin. Hematol. (IF 3.6) Pub Date : 2023-05-10 Steven P. Treon, Christopher J. Patterson, Ramon Garcia Sanz, Jesus San Miguel
Abstract not available
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 3.6) Pub Date : 2023-04-19
Abstract not available
-
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria Semin. Hematol. (IF 3.6) Pub Date : 2023-04-20 Steven P. Treon, Alessandra Tedeschi, Jesus San-Miguel, Ramon Garcia-Sanz, Kenneth C. Anderson, Eva Kimby, Monique C. Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S. Tam, Jorge J. Castillo, Pierre Morel, Meletios Dimopoulos, Roger G. Owen
Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment. Since the initial consensus reports of the 2nd International Workshop, there have been updates in the understanding of the mutational landscape of IgM related diseases, including the discovery and prevalence of
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia Semin. Hematol. (IF 3.6) Pub Date : 2023-04-06 Ramón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, Simone Ferrero, Stephanie Poulain, Jesus F. San-Miguel, Maria L. Guerrera, Daniela Drandi, Tina Bagratuni, Mary McMaster, Aldo M. Roccaro, Damien Roos-Weil, Merav Leiba, Yong Li, Luigi Qiu, Jian Hou, C. Fernandez De Larrea, Jorge J. Castillo, M. Dimopoulos, R.G. Owen, Z.R. Hunter
Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular
-
The epidemiology of Waldenström macroglobulinemia Semin. Hematol. (IF 3.6) Pub Date : 2023-03-31 Mary L. McMaster
Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the presence of lymphoplasmacytic lymphoma (LPL) in the bone marrow accompanied by a monoclonal immunoglobulin type M (IgM) in the serum. WM was first described only 80 years ago and became reportable in the US as a malignancy in 1988. Very little systematic research was conducted prior to 2000 to characterize
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management Semin. Hematol. (IF 3.6) Pub Date : 2023-03-29 E. Terpos, A.R. Branagan, R. García-Sanz, J. Trotman, L.M. Greenberger, D.M. Stephens, P. Morel, E. Kimby, A.M. Frustaci, E. Hatjiharissi, J. San-Miguel, M.A. Dimopoulos, S.P. Treon, V. Leblond
Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM). The key recommendations from IWWM-11 CP5 included the following: Booster vaccines for SARS-CoV-2 should be
-
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis Semin. Hematol. (IF 3.6) Pub Date : 2023-03-29 Giampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, Xinxin Cao, Meletios Dimopoulos, Ramon Garcia-Sanz, Moshe E. Gatt, Carlos Fernandez de Larrea, Jesus San-Miguel, Steven P. Treon, Monique C. Minnema
Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients Semin. Hematol. (IF 3.6) Pub Date : 2023-03-29 Christian Buske, Jorge J. Castillo, Jithma Prasad Abeykoon, Ranjana Advani, Suzanne O. Arulogun, Andrew R. Branagan, Xinxin Cao, Shirley D'Sa, Jian Hou, Prashant Kapoor, Efstathios Kastritis, Marie J. Kersten, Veronique LeBlond, Merav Leiba, Jeffrey V. Matous, Jonas Paludo, Lugui Qiu, Constantine S. Tam, Alessandra Tedeschi, Sheeba K. Thomas, Judith Trotman
Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM. The panel reiterated that watchful waiting remains the gold standard for asymptomatic patients without critically elevated IgM or compromised hematopoietic function. For first-line treatment,